Business
Aelis Farma announces the successful start of the recruitment of the Phase 2B clinical trial with AEF0217 for the treatment of behavioral and cognitive impairments of people with Down syndrome (Trisomy 21)
BORDEAUX, France, March 21, 2026--Regulatory News: Aelis Farma (ISIN: FR0014007ZB4 – Ticker: AELIS), a clinical-stage biopharmaceutical company specialized in the development of treatments for brain and peripheral diseases involving the CB1 receptor, announces today, on World Down Syndrome Day, the successful launch of its Phase 2B clinical trial with AEF0217 for the treatment of the behavioral and cognitive impairments associated with Down syndrome (Trisomy 21), with recruitment now underway ac
About this update from Aelis Farma Sa
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":480,"height":252,"url":"https://media.zenfs.com/en/business-wire.com/42a3b2c15f87ecff65ddc8531bc243a1"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/TeI422URrxFgpgkKdiCi8A--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTUwNA--/https://media.zenfs.com/en/business-wire.com/42a3b2c15f87ecff65ddc8531bc243a1","width":480,"height":252}},"lazy":false},{"type":"list","items":[{"val":[{"type":"text","content":"AEF0217 is a first-in-class Signalling Specific inhibitor of the CB1 receptor (CB1-SSi) developed as a treatment for impairments in adaptive behaviours and cognition in neurodevelopmental disorders, with Down syndrome as the first indication.","length":242,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"On World Down syndrome Day, Aelis Farma is happy to announce that the three countries involved in a Phase 2B clinical trial with AEF0217 in Down syndrome, are now actively recruiting.","length":183,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"This Phase 2B trial is expected to enroll 188 participants with down syndrome aged 16 to 32 years in clinical centers across France, Italy and Spain and evaluate the effects of AEF0217 on the behavioral and cognitive impairments of people with Down syndrome.","length":258,"tagName":"p","attribs":{}}]}],"tagName":"ul","bulletedList":true,"length":683,"olType":false},{"type":"text","content":"BORDEAUX, France, March 21, 2026--(BUSINESS WIRE)--Regulatory News:","length":67,"tagName":"p"},{"type":"text","content":"Aelis Farma (ISIN: FR0014007ZB4 – Ticker: AELIS), a clinical-stage biopharmaceutical company specialized in the development of treatments for brain and peripheral diseases involving the CB1 receptor, announces today, on World Down Syndrome Day, the successful launch of its Phase 2B clinical trial with AEF0217 for the treatment of the behavioral and cognitive impairments associated with Down syndrome (Trisomy 21), with recruitment now underway across the three countries involved (Spain, France and Italy).","length":509,"tagName":"p"},{"type":"text","content":"The first patient first visit (FPFV) was performed in December 2025 shortly after receiving initial regulatory approval, reflecting the Company’s ability to execute its clinica...